Pharmacodynamic effects of daclizumab in the intrathecal compartment

OBJECTIVE: It was previously demonstrated that daclizumab therapy normalizes cellular cerebrospinal fluid (CSF) abnormalities typical of multiple sclerosis (MS) in the majority of treated patients. However, CSF cells represent only the mobile portion of intrathecal immune responses. Therefore, we as...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ann Clin Transl Neurol
Auteurs principaux: Komori, Mika, Kosa, Peter, Stein, Jason, Zhao, Vivian, Blake, Andrew, Cherup, Jamie, Sheridan, James, Wu, Tianxia, Bielekova, Bibiana
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2017
Sujets:
Research Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497534/
https://ncbi.nlm.nih.gov/pubmed/28695148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.427
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires